2023年3月31日

7月20日2021 - 34斯德哥爾摩,瑞典- 7月20日,2021:方法治療持有AB(“否定療法”或“公司”)宣布,該公司已收到批準在納斯達克上市的第一個北增長市場(“第一北”)。方法治療也宣布,瑞典公司登記機關注冊公司的最近完成了問題的單位和交易的第一天是星期四,2021年7月22日。公司的股價將在短名稱“MODTX”和ISIN代碼SE0015987904和權證交易的係列1短名稱“MODTX 1”和SE0016075568 ISIN代碼。Sedermera Fondkommission是財務顧問和市場&公司法北歐AB是否定的法律顧問療法與單位的問題。北歐發行作為發行代理。關於清單的進一步信息,請聯係:Sedermera Fondkommission約翰•Ohd CEO,過渡治療電話:+ 46(0)70 766 80 97認證顧問對AB方法治療方法治療是一個瑞典的生物科技公司發展與關注sevuparin尚未被滿足的醫療需求高的疾病。公司近期重點是開發sevuparin膿毒症/膿毒性休克患者,病情嚴重,常常致命。膿毒症/膿毒性休克構成bacteria-induced狀態嚴重的係統性炎症。嚴重係統性炎症也可以從其他幾個發生嚴重的醫療事件如大手術、創傷、燒傷、自身免疫提到一些,也為sevuparin潛在的利益高需要的跡象。斯德哥爾摩卡羅林斯卡開發方法由AB(納斯達克:KDEV), KDEV投資AB,卡羅林斯卡開發AB和羅塞塔(資本),波羅的海和歐洲的基礎研究(Ostersjostiftelsen)和Praktikerinvest AB。關於sevuparin sevuparin臨床階段,是一個創新的專有多糖藥物多通道的作用機製,包括抗炎、anti-adhesive和anti-aggregate效果。 Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration. About severe systemic inflammation Severe systemic inflammation conditions (also known as systemic inflammatory response syndrome, SIRS) are feared complications of severe medical conditions such as infection, trauma, and major surgery. It is characterized by an uncontrolled systemic inflammatory response that can progress into shock and multi-organ failure. One such manifestation is septic shock, which is a leading cause of death in intensive care units worldwide, with mortality rates typically exceeding 30%. In systemic inflammation reactions, vascular hyper-permeability caused by the inflammatory response, may cause significant endothelial damage, plasma leakage and excessive edema formation. The pulmonary circulation is particularly vulnerable leading to respiratory distress, and in time more advanced multi-organ damage ensues. Neutrophil granulocytes, releasing an array of potent inflammatory mediators exhibiting permeability–increasing properties, are critically involved in the capillary-alveolar barrier breakdown. There is currently no pharmaceutical product available that can be specifically used to treat patients with uncontrolled systemic inflammation such as sepsis. The current standard of care for hospitalized patients relies on aggressive fluid therapy, vasopressors, oxygen, corticoid steroids and mechanical ventilation. Provided by: Cision